(0.26%) 5 560.25 points
(0.01%) 39 555 points
(0.40%) 20 120 points
(0.65%) $82.27
(0.82%) $2.71
(0.00%) $2 336.70
(0.66%) $29.45
(0.45%) $1 010.70
(0.15%) $0.935
(0.44%) $10.67
(0.03%) $0.791
(1.77%) $86.50
0.39% HKD 25.60
Live Chart Being Loaded With Signals
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China...
Stats | |
---|---|
Dzisiejszy wolumen | 181 700 |
Średni wolumen | 674 076 |
Kapitalizacja rynkowa | 33.45B |
EPS | HKD0.650 ( Q1 | 2024-03-31 ) |
Następna data zysków | ( HKD0.603 ) 2024-08-20 |
Last Dividend | HKD1.744 ( 2023-07-04 ) |
Next Dividend | HKD0 ( N/A ) |
P/E |
11.18 (Sector) 14.27 (Industry) 0 |
ATR14 | HKD0.0180 (0.07%) |
Wolumen Korelacja
Livzon Pharmaceutical Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Livzon Pharmaceutical Korelacja - Waluta/Towar
Livzon Pharmaceutical Finanse
Annual | 2023 |
Przychody: | HKD12.43B |
Zysk brutto: | HKD7.96B (64.08 %) |
EPS: | HKD2.10 |
FY | 2023 |
Przychody: | HKD12.43B |
Zysk brutto: | HKD7.96B (64.08 %) |
EPS: | HKD2.10 |
FY | 2022 |
Przychody: | HKD12.63B |
Zysk brutto: | HKD8.17B (64.68 %) |
EPS: | HKD2.04 |
FY | 2021 |
Przychody: | HKD12.06B |
Zysk brutto: | HKD7.81B (64.75 %) |
EPS: | HKD1.900 |
Financial Reports:
No articles found.
Livzon Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD1.744 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.221 | 2014-07-08 |
Last Dividend | HKD1.744 | 2023-07-04 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 10 | -- |
Total Paid Out | HKD9.31 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.01 | -- |
Div. Sustainability Score | 9.98 | |
Div.Growth Potential Score | 6.06 | |
Div. Directional Score | 8.02 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
04 Jul 2023 | HKD1.744 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
30 May 2022 | HKD1.512 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
01 Jun 2021 | HKD1.506 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
04 Jun 2020 | HKD1.253 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
03 Jul 2019 | HKD1.050 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
22 Jun 2018 | HKD1.455 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
05 Jul 2017 | HKD0.260 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
15 Jun 2016 | HKD0.270 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
02 Jul 2015 | HKD0.0444 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
08 Jul 2014 | HKD0.221 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2628.HK | Ex Dividend Knight | 2023-07-05 | Annually | 0 | 0.00% | |
0807.HK | Ex Dividend Knight | 2023-09-11 | Semi-Annually | 0 | 0.00% | |
1962.HK | Ex Dividend Junior | 2023-09-11 | Annually | 0 | 0.00% | |
0386.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
1443.HK | Ex Dividend Junior | 2023-10-04 | Annually | 0 | 0.00% | |
0046.HK | Ex Dividend Knight | 2023-08-31 | Semi-Annually | 0 | 0.00% | |
3848.HK | Ex Dividend Junior | 2023-07-04 | Annually | 0 | 0.00% | |
0991.HK | Ex Dividend Junior | 2023-06-30 | Sporadic | 0 | 0.00% | |
2196.HK | Ex Dividend Junior | 2023-07-31 | Annually | 0 | 0.00% | |
0595.HK | Ex Dividend Junior | 2023-09-06 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.161 | 1.500 | 6.77 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0786 | 1.200 | 7.38 | 8.86 | [0 - 0.3] |
returnOnEquityTTM | 0.142 | 1.500 | 9.53 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.799 | -1.000 | 2.01 | -2.01 | [0 - 1] |
currentRatioTTM | 2.06 | 0.800 | 4.69 | 3.75 | [1 - 3] |
quickRatioTTM | 1.802 | 0.800 | 4.11 | 3.29 | [0.8 - 2.5] |
cashRatioTTM | 1.338 | 1.500 | 3.68 | 5.52 | [0.2 - 2] |
debtRatioTTM | 0.141 | -1.500 | 7.64 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 24.70 | 1.000 | 1.962 | 1.962 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.14 | 2.00 | 8.62 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.25 | 2.00 | 8.37 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.244 | -1.500 | 9.02 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.645 | 1.000 | 2.58 | 2.58 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.206 | 1.000 | 7.88 | 7.88 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.087 | 1.000 | 5.07 | 5.07 | [0.2 - 2] |
assetTurnoverTTM | 0.487 | 0.800 | -0.0887 | -0.0709 | [0.5 - 2] |
Total Score | 9.98 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 11.12 | 1.000 | 8.98 | 0 | [1 - 100] |
returnOnEquityTTM | 0.142 | 2.50 | 9.70 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.25 | 2.00 | 8.92 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 7.41 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.14 | 2.00 | 8.62 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.799 | 1.500 | 2.01 | -2.01 | [0 - 1] |
pegRatioTTM | 1.600 | 1.500 | 2.67 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.316 | 1.000 | 4.60 | 0 | [0.1 - 0.5] |
Total Score | 6.06 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Livzon Pharmaceutical
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej